Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer

被引：22
|
作者：
Kappers, Ingrid [1 ]
Klomp, Houke M. [1 ]
Burgers, Jacobus A. [2 ]
Van Zandwijk, Nico [2 ]
Haas, Rick L. M. [3 ]
van Pel, Renee [4 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands
[4] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 25期
关键词：
D O I：
10.1200/JCO.2008.16.3709
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：4205 / 4207
页数：3
相关论文
共 50 条
  • [1] NEOADJUVANT CHEMOTHERAPY IN STAGE IIIA NON-SMALL-CELL LUNG-CANCER
    MILROY, R
    MACBETH, F
    THORAX, 1995, 50 : S25 - S30
  • [2] Neoadjuvant multimodal treatment of stage IIIA non-small-cell lung cancer
    Thomas, M
    Rube, C
    Semik, M
    Junker, K
    vonEiff, M
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 122 (33) : 993 - 998
  • [3] Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non-Small-Cell Lung Cancer
    Schaake, Eva E.
    Kappers, Ingrid
    Codrington, Henk E.
    Olmos, Renato A. Valdes
    Teertstra, Hendrik J.
    van Pel, Renee
    Burgers, Jacobus A.
    van Tinteren, Harm
    Klomp, Houke M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) : 2731 - 2738
  • [4] Management of non-small-cell lung cancer (stage IIIa)
    Gridelli, C
    Rossi, A
    Guerriero, C
    Ferrara, C
    Del Gaizo, F
    Colantuoni, G
    Salerno, V
    Nicolella, D
    TUMORI JOURNAL, 2003, : S103 - S105
  • [5] Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer
    Hill, Addie
    Gong, Jun
    Wilczynski, Sharon
    Mirza, Rizvan
    Erhunmwunsee, Loretta
    Salgia, Ravi
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (09) : 569 - +
  • [6] A PROSPECTIVE PHASE II STUDY OF INDUCTION ERLOTINIB THERAPY IN STAGE IIIA-N2 NON-SMALL-CELL LUNG CANCER
    Zhong, W. -Z.
    Yang, X. -N.
    Liao, R. -Q.
    Nie, Q.
    Su, J.
    Zhang, X. -C.
    An, S. -J.
    Zhou, Q.
    Yang, J. -J.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2012, 23 : 43 - 43
  • [7] CRITICAL ANALYSIS OF NEOADJUVANT THERAPY FOR STAGE-IIIA NON-SMALL-CELL LUNG-CANCER
    MURREN, JR
    BUZAID, AC
    HAIT, WN
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 143 (04): : 889 - 894
  • [8] Controversies in the management of stage IIIA non-small-cell lung cancer
    Santos, Edgardo S.
    Castrellon, Aurelio
    Blaya, Marcelo
    Raez, Luis E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (12) : 1913 - 1929
  • [9] Multidisciplinary Treatment of Stage IIIA Non-Small-Cell Lung Cancer
    Yendamuri, Sai
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (07) : 607 - +
  • [10] Multimodality therapy in stage IIIA non-small-cell lung cancer
    Kim, SY
    Lee, YS
    Jung, SS
    Yun, WJ
    Kim, JO
    Cho, MJ
    Lim, SR
    Kim, JS
    Roh, YH
    LUNG CANCER, 2004, 45 : S57 - S58
12345